SLC12A2

Across TCGA pan-cancer cohorts, SLC12A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC12A2 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC12A2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SLC12A2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SLC12A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.715	0.412	<.001	52	view →
CCRCC	DFS	Quartile	All	0.980	0.728	.006	11	view →
LUAD	DFS	Tertile	All	0.844	0.968	.005	8	view →
GBM	OS	Quartile	All	0.194	0.671	.005	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC12A2–PDAC (OS)

Open the PDAC breakdown →